Filing Flows

Filing Flows › Companies › Phibro Animal Health › Cash flow

Phibro Animal Health cash flow, quarter by quarter

Latest: Q1 FY27 · from the cash-flow statements filed with the SEC

Free cash flow$7.3M in Q1 FY27 · $21.7M over twelve months

Operating cash flow$26.1M
Capital spending−$18.8M
Free cash flow+$7.3M
Cash / net income0.9×
Cash conversion cycle204 days

Analysis

In Q1 FY27, Phibro Animal Health generated $26.1M of operating cash flow and spent $18.8M on capital projects, leaving free cash flow of $7.3M. That is $11.8M more than in Q1 FY26 (−$4.5M).

Over the twelve months to Sep 30, 2026, operating cash flow was $85.7M; the largest uses were capital spending ($64.1M), dividends ($19.5M), other financing ($18.1M); besides operations, cash came from net borrowing (+) / repaid (−) ($9.0M), other investing ($7.7M); the cash balance rose by $2.8M.

Operating cash flow was $26.1M against net income of $29.5M — 0.9× profit, less cash than reported earnings, worth checking against working capital. The largest differences: inventory −$33.9M, accrued liabilities −$25.6M, receivables +$16.2M.

Its cash conversion cycle was 204 days (receivables 55 + inventory 196 − payables 47).

Free cash flow

Phibro Animal Health: free cash flow by quarterPhibro Animal Health: free cash flow by quarter−$4.7MQ2 FY25$35.4MQ3 FY25$8.1MQ4 FY25−$4.5MQ1 FY26$8.3MQ2 FY26$890KQ3 FY26$5.2MQ4 FY26$7.3MQ1 FY27
Operating cash flow less capital spending.
Phibro Animal Health: operating cash flow against capital spendingPhibro Animal Health: operating cash flow against capital spendingOperating cash flowCapital spending$3.1M$7.8MQ2 FY25$43.2M$7.7MQ3 FY25$21.3M$13.1MQ4 FY25$9.3M$13.8MQ1 FY26$19.4M$11.1MQ2 FY26$16.2M$15.3MQ3 FY26$24.1M$18.9MQ4 FY26$26.1M$18.8MQ1 FY27
Latest (Q1 FY27): Operating cash flow $26.1M, Capital spending $18.8M.

Capital allocation, year by year

Phibro Animal Health: where the cash came from (up) and went (down), by fiscal yearPhibro Animal Health: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingCapital spendingAcquisitionsDividendsFY22: Operating cash flow $31.6MFY22: Net borrowing $50.0MFY22: Capital spending −$37.0MFY22: Acquisitions −$13.5MFY22: Dividends −$19.4M$81.6MFY22FY23: Operating cash flow $13.3MFY23: Net borrowing −$4.0MFY23: Capital spending −$51.8MFY23: Dividends −$19.4M$13.3MFY23FY24: Operating cash flow $87.6MFY24: Net borrowing $35.0MFY24: Capital spending −$41.2MFY24: Acquisitions −$3.3MFY24: Dividends −$19.4M$123MFY24FY25: Operating cash flow $80.1MFY25: Net borrowing −$89.0MFY25: Capital spending −$38.3MFY25: Acquisitions −$287MFY25: Dividends −$19.4M$80.1MFY25FY26: Operating cash flow $69.0MFY26: Net borrowing $29.0MFY26: Capital spending −$59.1MFY26: Dividends −$19.5M$98.0MFY26
Over these 5 years operating cash flow totalled $282M; the largest uses were acquisitions ($303M) and capital spending ($227M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$83.1M
Debt$611M
Net debt$528M
Due within a year$25.0M

Phibro Animal Health funds itself: free cash flow was $21.7M over the last twelve months, and $83.1M of cash and investments stands against $611M of debt ($25.0M due within a year, 3.3× covered by cash).

Where the cash came from and went

Phibro Animal Health: sources (+) and uses (−) of cash, Q1 FY27Phibro Animal Health: sources (+) and uses (−) of cash, Q1 FY27Operating cash flow$26.1MCapital spending−$18.8MCash drawn (+) / kept (−)−$14.1MOther investing$12.8MDividends−$4.9MOther financing−$762KExchange rates−$372K
Phibro Animal Health: sources (+) and uses (−) of cash, TTM to Q1 FY27Phibro Animal Health: sources (+) and uses (−) of cash, TTM to Q1 FY27Operating cash flow$85.7MCapital spending−$64.1MDividends−$19.5MOther financing−$18.1MNet borrowing (+) / repaid (−)$9.0MOther investing$7.7MCash drawn (+) / kept (−)−$2.8MExchange rates$2.0M

From profit to cash

Phibro Animal Health: net income to operating cash flow, Q1 FY27Phibro Animal Health: net income to operating cash flow, Q1 FY27Net income$29.5MDepreciation & amortization$13.6MStock-based pay$804KDeferred taxes$3.9MOther non-cash−$757KReceivables$16.2MInventory−$33.9MPayables$12.3MAccrued liabilities−$25.6MPrepaid and other assets$8.3MOperating cash flow$26.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q1 FY275519647204
Q4 FY265318645195
Q3 FY265118446190
Q2 FY265318950192
Q1 FY265617351178
Q4 FY255115146157
Q3 FY255016243170
Q2 FY255215541166

Every quarter

QuarterOperating cash flowCapital spendingAcquisitionsDividendsNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q1 FY27$26.1M−$18.8M—−$4.9M—−$14.1M$7.3M
Q4 FY26$24.1M−$18.9M—−$4.9M$1.0M−$6.5M$5.2M
Q3 FY26$16.2M−$15.3M—−$4.9M$8.0M$557K$890K
Q2 FY26$19.4M−$11.1M—−$4.9M−$8.0M$17.3M$8.3M
Q1 FY26$9.3M−$13.8M—−$4.9M$28.0M−$4.7M−$4.5M
Q4 FY25$21.3M−$13.1M$5.3M−$4.9M−$5.0M−$7.7M$8.1M
Q3 FY25$43.2M−$7.7M−$1.1M−$4.9M−$22.0M$6.7M$35.4M
Q2 FY25$3.1M−$7.8M—−$4.9M−$65.0M−$15.2M−$4.7M

Phibro Animal Health: income statement and cash flow

Phibro Animal Health, Q1 FY27: revenue $387M (+6% year over year), operating margin 12.8%. The chart follows the revenue to costs, profit and cash.

Phibro Animal Health: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.